Labeling and Drug Safety Communication Approaches to Loperamide Abuse

Daniel Woronow, Kimberley A. Swank,Eileen Wu,Cindy Kortepeter,Robert L. Levin

JACC: Clinical Electrophysiology（2017）

引用 1|浏览5

暂无评分

摘要

We read with great interest the loperamide study of Klein et al. [(1)][1]. The U.S. Food and Drug Administration (FDA) Division of Pharmacovigilance recently reviewed 48 cases of torsades de pointes and other serious cardiac adverse events with loperamide use received through the FDA Adverse Event

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要